Lingling Tian
@linglingtian.bsky.social
Editor, Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social
Co-Editor, Clinical Medicine Insights: Oncology | Rare Tumors
Co-Editor, Clinical Medicine Insights: Oncology | Rare Tumors
Happy Lunar New Year’s Eve! 🎇
Welcoming the Year of the Horse with gratitude for a year working alongside the global oncology community through Therapeutic Advances in Medical Oncology and Sage Oncology journals.
Wishing everyone health, energy, and new breakthroughs in the year ahead. 🐎✨ 马年大吉！
Welcoming the Year of the Horse with gratitude for a year working alongside the global oncology community through Therapeutic Advances in Medical Oncology and Sage Oncology journals.
Wishing everyone health, energy, and new breakthroughs in the year ahead. 🐎✨ 马年大吉！
February 16, 2026 at 8:15 AM
Happy Lunar New Year’s Eve! 🎇
Welcoming the Year of the Horse with gratitude for a year working alongside the global oncology community through Therapeutic Advances in Medical Oncology and Sage Oncology journals.
Wishing everyone health, energy, and new breakthroughs in the year ahead. 🐎✨ 马年大吉！
Welcoming the Year of the Horse with gratitude for a year working alongside the global oncology community through Therapeutic Advances in Medical Oncology and Sage Oncology journals.
Wishing everyone health, energy, and new breakthroughs in the year ahead. 🐎✨ 马年大吉！
New review highlights how PSMA‑targeted radioligand therapy, including 177Lu‑PSMA‑617 and emerging isotopes like 225Ac/161Tb, is reshaping advanced prostate cancer care. Combination strategies and precision dosimetry point to a rapidly evolving future.
🔗 buff.ly/WKhPij0
#ProstateCancer #RLT #PSMA
🔗 buff.ly/WKhPij0
#ProstateCancer #RLT #PSMA
February 13, 2026 at 8:15 AM
New review highlights how PSMA‑targeted radioligand therapy, including 177Lu‑PSMA‑617 and emerging isotopes like 225Ac/161Tb, is reshaping advanced prostate cancer care. Combination strategies and precision dosimetry point to a rapidly evolving future.
🔗 buff.ly/WKhPij0
#ProstateCancer #RLT #PSMA
🔗 buff.ly/WKhPij0
#ProstateCancer #RLT #PSMA
A new review examines how gut microbiota influence response and toxicity to neoadjuvant chemoradiotherapy in LARC. Beneficial species (e.g., Akkermansia, Alistipes) may enhance treatment effect, while pathogens like F. nucleatum may drive resistance.
🔗 buff.ly/PefDIka
🔗 buff.ly/PefDIka
February 10, 2026 at 8:15 AM
A new review examines how gut microbiota influence response and toxicity to neoadjuvant chemoradiotherapy in LARC. Beneficial species (e.g., Akkermansia, Alistipes) may enhance treatment effect, while pathogens like F. nucleatum may drive resistance.
🔗 buff.ly/PefDIka
🔗 buff.ly/PefDIka
Early NSCLC is entering a new era. Broad NGS profiling now identifies actionable mutations that guide adjuvant EGFR/ALK‑targeted therapy, influence immunotherapy decisions, and support ctDNA‑based MRD monitoring.
🔗 buff.ly/FKnT16B
#NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology
🔗 buff.ly/FKnT16B
#NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology
February 7, 2026 at 8:15 AM
Early NSCLC is entering a new era. Broad NGS profiling now identifies actionable mutations that guide adjuvant EGFR/ALK‑targeted therapy, influence immunotherapy decisions, and support ctDNA‑based MRD monitoring.
🔗 buff.ly/FKnT16B
#NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology
🔗 buff.ly/FKnT16B
#NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology
A nationwide analysis from Japan (n=741) reveals that 38% of patients with LA-NSCLC meet criteria for vulnerability—and this group shows markedly shorter OS after CCRT. Cachexia emerges as the strongest predictor of poor outcomes.
🔗 buff.ly/FjQd1Zu
🔗 buff.ly/FjQd1Zu
February 4, 2026 at 10:31 AM
A nationwide analysis from Japan (n=741) reveals that 38% of patients with LA-NSCLC meet criteria for vulnerability—and this group shows markedly shorter OS after CCRT. Cachexia emerges as the strongest predictor of poor outcomes.
🔗 buff.ly/FjQd1Zu
🔗 buff.ly/FjQd1Zu
The gut microbiome is emerging as a critical factor in pancreatic cancer pathogenesis and clinical outcomes.
Microbiome dysbiosis may contribute to tumor development and therapeutic resistance.
🔗 Full article: buff.ly/PXmWqNl
#PancreaticCancer #Microbiota
Microbiome dysbiosis may contribute to tumor development and therapeutic resistance.
🔗 Full article: buff.ly/PXmWqNl
#PancreaticCancer #Microbiota
January 30, 2026 at 8:15 AM
The gut microbiome is emerging as a critical factor in pancreatic cancer pathogenesis and clinical outcomes.
Microbiome dysbiosis may contribute to tumor development and therapeutic resistance.
🔗 Full article: buff.ly/PXmWqNl
#PancreaticCancer #Microbiota
Microbiome dysbiosis may contribute to tumor development and therapeutic resistance.
🔗 Full article: buff.ly/PXmWqNl
#PancreaticCancer #Microbiota
Belzutifan has demonstrated clinical activity across treatment lines in clear cell RCC.
Evidence supports its use as both front‑ and later‑line therapy, including in combination with TKIs.
🔗 Full article: buff.ly/joEgxsx
#RCC #KidneyCancer #Belzutifan
Evidence supports its use as both front‑ and later‑line therapy, including in combination with TKIs.
🔗 Full article: buff.ly/joEgxsx
#RCC #KidneyCancer #Belzutifan
January 27, 2026 at 8:15 AM
Belzutifan has demonstrated clinical activity across treatment lines in clear cell RCC.
Evidence supports its use as both front‑ and later‑line therapy, including in combination with TKIs.
🔗 Full article: buff.ly/joEgxsx
#RCC #KidneyCancer #Belzutifan
Evidence supports its use as both front‑ and later‑line therapy, including in combination with TKIs.
🔗 Full article: buff.ly/joEgxsx
#RCC #KidneyCancer #Belzutifan
⬇️ review unpacks how radiotherapy can trigger abscopal immunity: turning local DNA damage into systemic tumor control. Link: buff.ly/4lXAUWK
#Radiotherapy #AbscopalEffect #Immunotherapy #Oncology #cGASSTING #IO #CancerResearch
#Radiotherapy #AbscopalEffect #Immunotherapy #Oncology #cGASSTING #IO #CancerResearch
January 21, 2026 at 8:15 AM
⬇️ review unpacks how radiotherapy can trigger abscopal immunity: turning local DNA damage into systemic tumor control. Link: buff.ly/4lXAUWK
#Radiotherapy #AbscopalEffect #Immunotherapy #Oncology #cGASSTING #IO #CancerResearch
#Radiotherapy #AbscopalEffect #Immunotherapy #Oncology #cGASSTING #IO #CancerResearch
Why some pts with HR+ mBC develop resistance to CDK4/6i?
⬇️rev synthesizes evidence on intrinsic and acquired resistance, from RB1 mutations and germline variants to PIK3CA‑AKT‑mTOR activation, FGFR alterations, FAT1 loss, and dysregulated cyclin E/CDK2.
buff.ly/fhtTxrh
⬇️rev synthesizes evidence on intrinsic and acquired resistance, from RB1 mutations and germline variants to PIK3CA‑AKT‑mTOR activation, FGFR alterations, FAT1 loss, and dysregulated cyclin E/CDK2.
buff.ly/fhtTxrh
January 19, 2026 at 8:15 AM
Why some pts with HR+ mBC develop resistance to CDK4/6i?
⬇️rev synthesizes evidence on intrinsic and acquired resistance, from RB1 mutations and germline variants to PIK3CA‑AKT‑mTOR activation, FGFR alterations, FAT1 loss, and dysregulated cyclin E/CDK2.
buff.ly/fhtTxrh
⬇️rev synthesizes evidence on intrinsic and acquired resistance, from RB1 mutations and germline variants to PIK3CA‑AKT‑mTOR activation, FGFR alterations, FAT1 loss, and dysregulated cyclin E/CDK2.
buff.ly/fhtTxrh
KRAS G12C is the most common KRAS mutation in NSCLC. With targeted inhibitors like sotorasib and adagrasib approved, a review highlights how immunotherapy and combination strategies are reshaping treatment for advanced KRAS G12C - mutant lung cancer.
🔗 buff.ly/fzLtytC
🔗 buff.ly/fzLtytC
January 16, 2026 at 8:15 AM
KRAS G12C is the most common KRAS mutation in NSCLC. With targeted inhibitors like sotorasib and adagrasib approved, a review highlights how immunotherapy and combination strategies are reshaping treatment for advanced KRAS G12C - mutant lung cancer.
🔗 buff.ly/fzLtytC
🔗 buff.ly/fzLtytC
🔥Lung Cancer remains the leading cause of cancer deaths. While ICIs have improved outcomes, many patients never respond or become resistant. This rev explores ACT (CAR‑T, TCR‑T, and TILs) as the next frontier for lung cancer treatment.
🔗 buff.ly/dYTNRzP
#LungCancer #CellTherapy
🔗 buff.ly/dYTNRzP
#LungCancer #CellTherapy
January 14, 2026 at 8:15 AM
🔥Lung Cancer remains the leading cause of cancer deaths. While ICIs have improved outcomes, many patients never respond or become resistant. This rev explores ACT (CAR‑T, TCR‑T, and TILs) as the next frontier for lung cancer treatment.
🔗 buff.ly/dYTNRzP
#LungCancer #CellTherapy
🔗 buff.ly/dYTNRzP
#LungCancer #CellTherapy
Esophageal squamous cell carcinoma (ESCC) accounts for over 90% of esophageal cancer cases in China and still carries a 5‑yr survival rate under 30%. A review highlights an emerging factor in its development: the oral & esophageal microbiota.
🔗 buff.ly/rhqta16
#ESCC
🔗 buff.ly/rhqta16
#ESCC
January 12, 2026 at 8:15 AM
Esophageal squamous cell carcinoma (ESCC) accounts for over 90% of esophageal cancer cases in China and still carries a 5‑yr survival rate under 30%. A review highlights an emerging factor in its development: the oral & esophageal microbiota.
🔗 buff.ly/rhqta16
#ESCC
🔗 buff.ly/rhqta16
#ESCC
🔥Highly Cited 'Rare epithelial GCs: a review of the current treatment knowledge' addresses rare gastric tumor subtypes (~5% of epithelial gastric cancers). GC remains one of the most lethal cancers, with varied features by location, histology, and molecular profile.
🔗 buff.ly/I1ns2Qo
#GastricCancer
🔗 buff.ly/I1ns2Qo
#GastricCancer
January 9, 2026 at 8:15 AM
🔥Highly Cited 'Rare epithelial GCs: a review of the current treatment knowledge' addresses rare gastric tumor subtypes (~5% of epithelial gastric cancers). GC remains one of the most lethal cancers, with varied features by location, histology, and molecular profile.
🔗 buff.ly/I1ns2Qo
#GastricCancer
🔗 buff.ly/I1ns2Qo
#GastricCancer
🔥Top 1% Highly Cited Article!
OC remains the most lethal gyne malignancy - nearly 70% of cases present at stage III or IV with poor survival. Current screening tools lack the sensitivity and specificity needed for early detection.
🔗 Read ➡ buff.ly/J8LCbWx
#OvarianCancer #CancerResearch
OC remains the most lethal gyne malignancy - nearly 70% of cases present at stage III or IV with poor survival. Current screening tools lack the sensitivity and specificity needed for early detection.
🔗 Read ➡ buff.ly/J8LCbWx
#OvarianCancer #CancerResearch
January 7, 2026 at 8:15 AM
🔥Top 1% Highly Cited Article!
OC remains the most lethal gyne malignancy - nearly 70% of cases present at stage III or IV with poor survival. Current screening tools lack the sensitivity and specificity needed for early detection.
🔗 Read ➡ buff.ly/J8LCbWx
#OvarianCancer #CancerResearch
OC remains the most lethal gyne malignancy - nearly 70% of cases present at stage III or IV with poor survival. Current screening tools lack the sensitivity and specificity needed for early detection.
🔗 Read ➡ buff.ly/J8LCbWx
#OvarianCancer #CancerResearch
Paclitaxel + PD-1/PD-L1 inhibitors: What works best for TNBC?
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
January 5, 2026 at 8:15 AM
Paclitaxel + PD-1/PD-L1 inhibitors: What works best for TNBC?
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
This systematic review (4,626 patients) shows Durvalumab + Paclitaxel offers the strongest survival benefit, while Pembrolizumab excels in pCR.
Read the full findings: buff.ly/xFpuARX
#BreastCancer #TNBC #Immunotherapy #OncologyResearch
2025 was a year of growth for Therapeutic Advances in Medical Oncology, and also for me! 🧵 Here’s what we achieved together:
#Oncology #CancerResearch #YearInReview
#Oncology #CancerResearch #YearInReview
December 29, 2025 at 8:15 AM
2025 was a year of growth for Therapeutic Advances in Medical Oncology, and also for me! 🧵 Here’s what we achieved together:
#Oncology #CancerResearch #YearInReview
#Oncology #CancerResearch #YearInReview
This rev explores how metabolic reprogramming of CAFs in the tumor microenvironment drives cancer progression - and why targeting CAF metabolism could transform chemotherapy and immunotherapy.
Read more: buff.ly/dFoo90l
#CancerResearch #TumorMicroenvironment #OncologyInnovation #PrecisionMedicine
Read more: buff.ly/dFoo90l
#CancerResearch #TumorMicroenvironment #OncologyInnovation #PrecisionMedicine
December 26, 2025 at 8:15 AM
This rev explores how metabolic reprogramming of CAFs in the tumor microenvironment drives cancer progression - and why targeting CAF metabolism could transform chemotherapy and immunotherapy.
Read more: buff.ly/dFoo90l
#CancerResearch #TumorMicroenvironment #OncologyInnovation #PrecisionMedicine
Read more: buff.ly/dFoo90l
#CancerResearch #TumorMicroenvironment #OncologyInnovation #PrecisionMedicine
3 oncology articles with high Altmetric scores in 2025 at TAM! Covering renal cell carcinoma, gastric cancer, and leukemia. 🧵
#Oncology #CancerResearch #Altmetrics
buff.ly/9PQBbTR
#Oncology #CancerResearch #Altmetrics
buff.ly/9PQBbTR
December 24, 2025 at 8:15 AM
3 oncology articles with high Altmetric scores in 2025 at TAM! Covering renal cell carcinoma, gastric cancer, and leukemia. 🧵
#Oncology #CancerResearch #Altmetrics
buff.ly/9PQBbTR
#Oncology #CancerResearch #Altmetrics
buff.ly/9PQBbTR
Clinical Medicine Insights: Oncology - 2025 Year in Review ✨📚
2025 Highlights
Articles published: 60+ 📝
Countries represented: 20+ 🌍
Thanks to our contributors, we anticipate new initiatives and collaborations in 2026.
🔗 buff.ly/yERWBfX
#Oncology #TranslationalResearch #YearInReview
2025 Highlights
Articles published: 60+ 📝
Countries represented: 20+ 🌍
Thanks to our contributors, we anticipate new initiatives and collaborations in 2026.
🔗 buff.ly/yERWBfX
#Oncology #TranslationalResearch #YearInReview
December 22, 2025 at 8:15 AM
Clinical Medicine Insights: Oncology - 2025 Year in Review ✨📚
2025 Highlights
Articles published: 60+ 📝
Countries represented: 20+ 🌍
Thanks to our contributors, we anticipate new initiatives and collaborations in 2026.
🔗 buff.ly/yERWBfX
#Oncology #TranslationalResearch #YearInReview
2025 Highlights
Articles published: 60+ 📝
Countries represented: 20+ 🌍
Thanks to our contributors, we anticipate new initiatives and collaborations in 2026.
🔗 buff.ly/yERWBfX
#Oncology #TranslationalResearch #YearInReview
🔥 Therapeutic Advances in Medical OncologyTop 3 most talked-about lung cancer articles of the year are here! These papers earned the highest Altmetric attention.
Let’s dive in 👇
#LungCancer #Oncology #Altmetric
buff.ly/w0BcwqH
Let’s dive in 👇
#LungCancer #Oncology #Altmetric
buff.ly/w0BcwqH
December 20, 2025 at 1:24 AM
🔥 Therapeutic Advances in Medical OncologyTop 3 most talked-about lung cancer articles of the year are here! These papers earned the highest Altmetric attention.
Let’s dive in 👇
#LungCancer #Oncology #Altmetric
buff.ly/w0BcwqH
Let’s dive in 👇
#LungCancer #Oncology #Altmetric
buff.ly/w0BcwqH
AI is transforming colorectal cancer care. This Clinical Medicine Insights: Oncology review explores how machine learning and deep learning enable personalized treatment strategies and prognosis prediction. Read more: buff.ly/fqj2sqF
#ColorectalCancer #AIinMedicine #PrecisionMedicine
#ColorectalCancer #AIinMedicine #PrecisionMedicine
December 17, 2025 at 8:15 AM
AI is transforming colorectal cancer care. This Clinical Medicine Insights: Oncology review explores how machine learning and deep learning enable personalized treatment strategies and prognosis prediction. Read more: buff.ly/fqj2sqF
#ColorectalCancer #AIinMedicine #PrecisionMedicine
#ColorectalCancer #AIinMedicine #PrecisionMedicine
🔥 Our Top 3 most talked-about breast cancer articles of the year are here! These papers earned the highest Altmetric attention.
Let’s dive in 👇
#BreastCancer #Oncology #Altmetric
buff.ly/w0BcwqH
Let’s dive in 👇
#BreastCancer #Oncology #Altmetric
buff.ly/w0BcwqH
December 15, 2025 at 12:44 AM
🔥 Our Top 3 most talked-about breast cancer articles of the year are here! These papers earned the highest Altmetric attention.
Let’s dive in 👇
#BreastCancer #Oncology #Altmetric
buff.ly/w0BcwqH
Let’s dive in 👇
#BreastCancer #Oncology #Altmetric
buff.ly/w0BcwqH
Gumarontinib shows promise in driver-gene negative NSCLC with MET overexpression: pooled analysis (n=32) found ORR 37.5%, DCR 81.3%, median PFS 6.9 months, OS 17 months. Safety manageable (edema, hypoalbuminemia). Further trials warranted. #LungCancer #Oncology #ClinicalTrials buff.ly/NfCKkNQ
December 12, 2025 at 8:15 AM
Gumarontinib shows promise in driver-gene negative NSCLC with MET overexpression: pooled analysis (n=32) found ORR 37.5%, DCR 81.3%, median PFS 6.9 months, OS 17 months. Safety manageable (edema, hypoalbuminemia). Further trials warranted. #LungCancer #Oncology #ClinicalTrials buff.ly/NfCKkNQ
Capecitabine + temozolomide (CapTem) shows promise in atypical thymic carcinoids: ORR 15.8%, DCR 89.5%, median PFS 13 months. Age >50 & high platelet-to-lymphocyte ratio predict poorer outcomes. Well tolerated, with rare severe toxicities. #Oncology #NeuroendocrineTumors
buff.ly/UucHZlI
buff.ly/UucHZlI
December 10, 2025 at 8:15 AM
Capecitabine + temozolomide (CapTem) shows promise in atypical thymic carcinoids: ORR 15.8%, DCR 89.5%, median PFS 13 months. Age >50 & high platelet-to-lymphocyte ratio predict poorer outcomes. Well tolerated, with rare severe toxicities. #Oncology #NeuroendocrineTumors
buff.ly/UucHZlI
buff.ly/UucHZlI
New study in Chinese patients with prostate cancer: 3.75 mg triptorelin acetate microspheres achieved testosterone suppression in 97.6% of cases, with sustained release & manageable safety profile. Promising option for advanced & metastatic disease. #Oncology #ProstateCancer buff.ly/uzgZKo6
December 8, 2025 at 8:15 AM
New study in Chinese patients with prostate cancer: 3.75 mg triptorelin acetate microspheres achieved testosterone suppression in 97.6% of cases, with sustained release & manageable safety profile. Promising option for advanced & metastatic disease. #Oncology #ProstateCancer buff.ly/uzgZKo6